SAEs, Intermediate trial duration: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons‐Random Effects Model
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% Crl)
SD ETN SC + PL	MTX + PL	1.06 (0.34,3.38)	1.06 (0.37,2.68)	0.01 (‐0.08,0.19)
SD INF IV + MTX		0.52 (0.22,1.19)	0.55 (0.25,1.16)	‐0.05 (‐0.10,0.02)
SD ETN SC + MTX		0.77 (0.27,2.20)	0.79 (0.30,1.94)	‐0.02 (‐0.09,0.11)
SD ABA IV + MTX		0.73 (0.26,1.99)	0.76 (0.29,1.78)	‐0.03 (‐0.09,0.09)
SD RITUX IV + MTX		0.74 (0.27,1.96)	0.76 (0.30,1.76)	‐0.03 (‐0.09,0.09)
LD ETN SC + PL		0.72 (0.22,2.50)	0.75 (0.24,2.13)	‐0.03 (‐0.10,0.13)
LD RITUX IV + MTX		0.70 (0.25,1.86)	0.73 (0.28,1.69)	‐0.03 (‐0.09,0.08)
LD ABA IV + MTX		1.16 (0.44,3.19)	1.14 (0.47,2.55)	0.02 (‐0.07,0.18)
LD ETN SC + MTX		0.42 (0.12,1.34)	0.46 (0.14,1.29)	‐0.06 (‐0.11,0.03)
HD INF IV + MTX		0.96 (0.37,2.51)	0.96 (0.40,2.14)	0.00 (‐0.08,0.13)
SD INF IV + MTX	SD ETN SC + PL	0.49 (0.12,1.98)	0.52 (0.15,1.87)	‐0.06 (‐0.24,0.05)
SD ETN SC + MTX		0.74 (0.15,3.24)	0.76 (0.20,2.84)	‐0.03 (‐0.21,0.12)
SD ABA IV + MTX		0.68 (0.15,3.17)	0.72 (0.20,2.78)	‐0.04 (‐0.22,0.11)
SD RITUX IV + MTX		0.69 (0.15,3.08)	0.72 (0.20,2.72)	‐0.03 (‐0.22,0.11)
LD ETN SC + PL		0.69 (0.20,2.19)	0.72 (0.24,1.98)	‐0.03 (‐0.18,0.08)
LD RITUX IV + MTX		0.65 (0.14,2.89)	0.68 (0.19,2.56)	‐0.04 (‐0.22,0.10)
LD ABA IV + MTX		1.10 (0.25,4.94)	1.08 (0.31,4.01)	0.01 (‐0.18,0.19)
LD ETN SC + MTX		0.40 (0.08,2.05)	0.43 (0.10,1.91)	‐0.07 (‐0.25,0.05)
HD INF IV + MTX		0.90 (0.20,4.07)	0.91 (0.25,3.43)	‐0.01 (‐0.20,0.15)
SD ETN SC + MTX	SD INF IV + MTX	1.46 (0.40,5.88)	1.42 (0.42,4.88)	0.03 (‐0.06,0.17)
SD ABA IV + MTX		1.42 (0.38,5.13)	1.38 (0.41,4.38)	0.02 (‐0.06,0.15)
SD RITUX IV + MTX		1.42 (0.39,5.12)	1.38 (0.42,4.36)	0.02 (‐0.06,0.15)
LD ETN SC + PL		1.40 (0.31,6.27)	1.36 (0.34,5.13)	0.02 (‐0.07,0.18)
LD RITUX IV + MTX		1.36 (0.37,4.84)	1.33 (0.40,4.16)	0.02 (‐0.07,0.14)
LD ABA IV + MTX		2.26 (0.63,8.37)	2.09 (0.66,6.45)	0.07 (‐0.03,0.23)
LD ETN SC + MTX		0.82 (0.19,3.39)	0.83 (0.21,3.09)	‐0.01 (‐0.09,0.09)
HD INF IV + MTX		1.86 (0.65,5.30)	1.75 (0.68,4.44)	0.05 (‐0.03,0.17)
SD ABA IV + MTX	SD ETN SC + MTX	0.94 (0.22,4.00)	0.94 (0.26,3.47)	‐0.01 (‐0.14,0.13)
SD RITUX IV + MTX		0.94 (0.22,3.95)	0.95 (0.26,3.44)	0.00 (‐0.14,0.13)
LD ETN SC + PL		0.93 (0.20,4.50)	0.94 (0.23,3.79)	‐0.01 (‐0.15,0.16)
LD RITUX IV + MTX		0.92 (0.22,3.75)	0.92 (0.25,3.28)	‐0.01 (‐0.15,0.12)
LD ABA IV + MTX		1.51 (0.36,6.41)	1.43 (0.41,5.12)	0.04 (‐0.11,0.21)
LD ETN SC + MTX		0.55 (0.16,1.81)	0.58 (0.18,1.72)	‐0.04 (‐0.15,0.04)
HD INF IV + MTX		1.25 (0.30,5.12)	1.22 (0.34,4.29)	0.02 (‐0.13,0.16)
SD RITUX IV + MTX	SD ABA IV + MTX	0.99 (0.25,4.19)	0.99 (0.29,3.63)	0.00 (‐0.13,0.13)
LD ETN SC + PL		1.00 (0.21,4.82)	1.00 (0.24,3.99)	0.00 (‐0.14,0.16)
LD RITUX IV + MTX		0.94 (0.24,4.00)	0.95 (0.28,3.49)	0.00 (‐0.13,0.12)
LD ABA IV + MTX		1.61 (0.60,4.49)	1.52 (0.64,3.74)	0.05 (‐0.05,0.18)
LD ETN SC + MTX		0.58 (0.12,2.77)	0.60 (0.14,2.54)	‐0.03 (‐0.16,0.08)
HD INF IV + MTX		1.30 (0.33,5.25)	1.26 (0.37,4.39)	0.02 (‐0.11,0.17)
LD ETN SC + PL	SD RITUX IV + MTX	0.98 (0.21,4.73)	0.99 (0.24,3.95)	0.00 (‐0.13,0.16)
LD RITUX IV + MTX		0.95 (0.35,2.71)	0.96 (0.39,2.46)	0.00 (‐0.09,0.09)
LD ABA IV + MTX		1.61 (0.41,6.48)	1.52 (0.45,5.08)	0.05 (‐0.09,0.22)
LD ETN SC + MTX		0.58 (0.12,2.63)	0.60 (0.14,2.42)	‐0.03 (‐0.16,0.07)
HD INF IV + MTX		1.30 (0.34,5.23)	1.26 (0.38,4.30)	0.02 (‐0.11,0.17)
LD RITUX IV + MTX	LD ETN SC + PL	0.98 (0.19,4.42)	0.98 (0.24,3.88)	0.00 (‐0.17,0.12)
LD ABA IV + MTX		1.61 (0.34,7.65)	1.52 (0.40,6.07)	0.04 (‐0.12,0.22)
LD ETN SC + MTX		0.60 (0.12,3.00)	0.62 (0.14,2.76)	‐0.03 (‐0.19,0.08)
HD INF IV + MTX		1.33 (0.28,6.29)	1.29 (0.33,5.20)	0.03 (‐0.14,0.17)
LD ABA IV + MTX	LD RITUX IV + MTX	1.67 (0.42,6.88)	1.58 (0.47,5.38)	0.05 (‐0.09,0.22)
LD ETN SC + MTX		0.60 (0.13,2.82)	0.62 (0.15,2.58)	‐0.03 (‐0.15,0.08)
HD INF IV + MTX		1.35 (0.35,5.49)	1.31 (0.39,4.57)	0.03 (‐0.10,0.17)
LD ETN SC + MTX	LD ABA IV + MTX	0.36 (0.07,1.68)	0.40 (0.10,1.59)	‐0.08 (‐0.25,0.04)
HD INF IV + MTX		0.82 (0.21,3.17)	0.84 (0.26,2.71)	‐0.02 (‐0.19,0.13)
HD INF IV + MTX	LD ETN SC + MTX	2.26 (0.52,10.49)	2.11 (0.56,8.68)	0.06 (‐0.06,0.20)
Random‐Effect Model	Residual Deviance	16.48 vs 17 data points
	Deviance Information Criteria	105.18
Fixed‐Effect Model	Residual Deviance	16.25 vs 17 data points
	Deviance Information Criteria	104.718
Note:
Total Patients	2277
Total Studies	6
2‐arm	1
5‐arm	5